Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients.

Griffin, A D; Perry, A S; Fleming, D M

Griffin, A D; Perry, A S; Fleming, D M.

Affiliation

Griffin AD; GlaxoWellcome Research and Development, Greenford, UK.

Pharmacoeconomics ; 19(3): 293-301, 2001.

Article in En | MEDLINE | ID: mdl-11303417

Subject(s)

Antiviral Agents/therapeutic use; Influenza A virus; Influenza B virus; Influenza, Human/drug therapy; Sialic Acids/therapeutic use; Administration, Inhalation; Adult; Aged; Cost-Benefit Analysis; Female; Guanidines; Humans; Influenza, Human/economics; Male; Middle Aged; Pyrans; Sialic Acids/administration & dosage; Zanamivir

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Influenza A virus / Influenza B virus / Sialic Acids / Influenza, Human Type of study: Clinical_trials / Etiology_studies / Health_economic_evaluation / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Pharmacoeconomics Journal subject: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2001 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links